GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

ITCA 650

Company
Intarcia Therapeutics
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
12 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

12 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for ITCA 650 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT05356104

    GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)

    Not yet reported Chinese University of Hong Kong 110 participants Est. completion 2027-12 2 sites
    Other conditions: Cerebral Small Vessel Disease
    View official trial listing →
  • Recruiting NCT NCT05482789

    Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes

    Not yet reported Maisa N. Feghali, MD 13 participants Est. completion 2026-12-31 1 site
    Other conditions: Gestational Diabetes
    View official trial listing →
  • Recruiting NCT NCT05662189

    Assessment of Pancreatic Beta Cell Mass and Function by Positron Emission Tomography Imaging in Human Diabetes Mellitus

    Not yet reported Azienda Ospedaliero-Universitaria di Parma 70 participants Est. completion 2025-12 1 site
    Other conditions: Type1diabetes, Type2diabetes, Pre Diabetes, Hyperinsulinism
    View official trial listing →
  • Recruiting NCT NCT05663515

    A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs

    AstraZeneca 24000 participants Est. completion 2026-10-01 8 sites
    Other conditions: Pancreatic Cancer
    View official trial listing →
  • Recruiting NCT NCT06256419

    Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM

    Not yet reported The Affiliated Hospital of Xuzhou Medical University 300 participants Est. completion 2028-01-31 1 site
    Type 2 diabetes Other conditions: Susceptibility, Genetic
    View official trial listing →
  • Recruiting NCT NCT06725693

    Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease

    Tianjin Medical University 500 participants Est. completion 2027-11-01 3 sites
    Other conditions: GLP1-R-related Disease, Tumor, Insulinoma, Positron Emission Tomography
    View official trial listing →
  • Recruiting NCT NCT06888167

    Food (Poly)Phenol Metabotypes and Beta-cell Mass and Function.

    Not yet reported Azienda Ospedaliero-Universitaria di Parma 40 participants Est. completion 2026-02-28 1 site
    Other conditions: Healthy Volunteer
    View official trial listing →
  • Recruiting NCT NCT07309094

    Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD

    Cardenal Herrera University 250 participants Est. completion 2028-12-31 1 site
    Chronic kidney diseaseType 2 diabetes Other conditions: Obesity
    View official trial listing →
  • Recruiting NCT NCT07347080

    A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus

    Not yet reported The First Affiliated Hospital of Henan University of Science and Technology 9 participants Est. completion 2026-08-31 1 site
    Type 2 diabetes
    View official trial listing →
  • Recruiting NCT NCT07497399

    Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

    Not yet reported Johns Hopkins University 120 participants Est. completion 2030-01 2 sites
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Recruiting NCT NCT07702461

    Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists

    Ohio State University 300 participants Est. completion 2027-01 1 site
    Other conditions: Obesity & Overweight, Diabetes (DM)
    View official trial listing →
  • Recruiting NCT NCT07808879

    Comparison of [68Ga]Ga-HBED-CC-PEG6-Exendin-4 and [68Ga]Ga-HBED-CC-Exendin-4 PET/CT for Insulinoma Localization

    Not yet reported Peking Union Medical College Hospital 20 participants Est. completion 2027-09-30 1 site
    Other conditions: Insulinoma
    View official trial listing →
  • Completed NCT NCT00035984

    Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus

    Not yet reported AstraZeneca 734 participants Est. completion 2003-08 100 sites
    Other conditions: Diabetes Mellitus, Non-Insulin-Dependent
    View official trial listing →
  • Completed NCT NCT00039013

    Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

    Not yet reported AstraZeneca 336 participants Est. completion 2003-06 129 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00039026

    Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea

    Not yet reported AstraZeneca 377 participants Est. completion 2003-08 126 sites
    Other conditions: Diabetes Mellitus, Non-Insulin-Dependent
    View official trial listing →
  • Completed NCT NCT00044668

    Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination

    Not yet reported AstraZeneca 155 participants Est. completion 2005-09 3 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00044694

    Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus

    Not yet reported AstraZeneca 156 participants Est. completion 2003-05 33 sites
    Other conditions: Diabetes Mellitus, Non-Insulin-Dependent
    View official trial listing →
  • Completed NCT NCT00064714

    Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes

    Not yet reported AstraZeneca 47 participants Est. completion 2008-03 1 site
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT00082381

    Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin

    Not yet reported AstraZeneca 551 participants Est. completion 2008-07 91 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00082407

    Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin

    Not yet reported AstraZeneca 505 participants Est. completion 2008-07 69 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00085969

    Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus

    Not yet reported AstraZeneca 99 participants Est. completion 2004-01 23 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00097500

    Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes

    Not yet reported AstraZeneca 69 participants Est. completion 2009-12 3 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00099320

    Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin

    Not yet reported AstraZeneca 182 participants Est. completion 2005-08 51 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00099333

    Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents

    Not yet reported AstraZeneca 49 participants Est. completion 2005-08 5 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00099619

    Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy

    Not yet reported AstraZeneca 138 participants Est. completion 2005-08 26 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00103935

    Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes

    Not yet reported AstraZeneca 45 participants Est. completion 2005-10 7 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00111540

    Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes

    Not yet reported AstraZeneca 456 participants Est. completion 2006-09 60 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00135330

    An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus

    Not yet reported AstraZeneca 137 participants Est. completion 2008-07 19 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00241423

    Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes

    Not yet reported AstraZeneca 30 participants Est. completion 2007-06 2 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00254254

    A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus

    Not yet reported AstraZeneca 13 participants Est. completion 2007-02 5 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00254800

    The Effects of Exenatide on Oral Contraceptive Pharmacokinetics in Healthy Females

    Not yet reported AstraZeneca 38 participants Est. completion 2006-08 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00259896

    In-patient Study in Patients With Type 2 Diabetes Mellitus

    Not yet reported GlaxoSmithKline 30 participants
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00308139

    Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)

    Not yet reported AstraZeneca 303 participants Est. completion 2014-08 25 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00313001

    Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.

    Not yet reported Novo Nordisk A/S 373 participants Est. completion 2007-07 1 site
    Type 2 diabetes Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT00324363

    Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin

    Not yet reported AstraZeneca 466 participants Est. completion 2007-04 14 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00344851

    Exenatide and Metformin Therapy in Overweight Women With PCOS

    Not yet reported Metabolic Center of Louisiana Research Foundation 60 participants Est. completion 2007-06 1 site
    Other conditions: Polycystic Ovary Syndrome
    View official trial listing →
  • Completed NCT NCT00353834

    The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes

    Not yet reported Joslin Diabetes Center 72 participants Est. completion 2010-09 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00359762

    Exenatide Versus Glimepiride in Patients With Type 2 Diabetes

    Not yet reported AstraZeneca 1029 participants Est. completion 2011-03 114 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00359879

    Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 Diabetes

    Not yet reported AstraZeneca 377 participants Est. completion 2007-07 15 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00360334

    A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients

    Not yet reported AstraZeneca 235 participants Est. completion 2008-04 31 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00375492

    Effect on Weight Loss of Exenatide Versus Placebo

    Not yet reported AstraZeneca 196 participants Est. completion 2008-02 10 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00381342

    Safety and Efficacy of Exenatide as Monotherapy

    Not yet reported AstraZeneca 233 participants Est. completion 2007-09 19 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00382239

    A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes

    Not yet reported AstraZeneca 153 participants Est. completion 2007-05 14 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00434954

    Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes

    Not yet reported AstraZeneca 494 participants Est. completion 2009-06 39 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00456300

    Role of Exenatide in Type 1 Diabetes

    Not yet reported Montefiore Medical Center 11 participants Est. completion 2009-03 1 site
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT00456885

    The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women

    Not yet reported Beth Israel Deaconess Medical Center 41 participants Est. completion 2010-09 1 site
    Prediabetes Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT00477581

    A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus

    Not yet reported AstraZeneca 102 participants Est. completion 2007-09 19 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00500370

    A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients

    Not yet reported AstraZeneca 163 participants Est. completion 2008-02 16 sites
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT00508287

    Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes

    Not yet reported Bristol-Myers Squibb 36 participants Est. completion 2007-11 3 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00516048

    An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes

    Not yet reported AstraZeneca 58 participants Est. completion 2008-04 13 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00516074

    A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes

    Not yet reported AstraZeneca 54 participants Est. completion 2008-04 6 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00517283

    A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes

    Not yet reported AstraZeneca 17 participants Est. completion 2005-06 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00518115

    Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only

    Not yet reported GlaxoSmithKline 361 participants Est. completion 2008-05 163 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00518882

    Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes

    Not yet reported Novo Nordisk A/S 467 participants Est. completion 2009-04 125 sites
    Type 2 diabetes Other conditions: Diabetes
    View official trial listing →
  • Terminated NCT NCT00529204

    Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease

    Not yet reported University of California, Davis 1 participants Est. completion 2010-02 1 site
    Other conditions: Diabetes Complications, Fatty Liver
    View official trial listing →
  • Completed NCT NCT00546728

    The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-Diabetes

    Not yet reported St. Paul Heart Clinic 50 participants Est. completion 2011-07 2 sites
    Prediabetes
    View official trial listing →
  • Completed NCT NCT00551343

    Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome

    Not yet reported Garvan Institute of Medical Research 20 participants Est. completion 2008-09 1 site
    Other conditions: Prader-Willi Syndrome
    View official trial listing →
  • Completed NCT NCT00560417

    Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide

    Not yet reported Eli Lilly and Company 339 participants Est. completion 2009-12 52 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00566813

    Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression

    Not yet reported, Not yet reported University of Illinois at Chicago 10 participants Est. completion 2020-07-15 1 site
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT00569907

    Observational Study of Interstitial Glucose Monitoring With Continuous Glucose Monitoring to Track Patients Treated With Exenatide

    HealthPartners Institute 18 participants Est. completion 2009-05 1 site
    Type 2 diabetes
    View official trial listing →
  • Withdrawn NCT NCT00572689

    Pilot Study of Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes

    Not yet reported Georgetown University Est. completion 2015-08 2 sites
    Other conditions: Gestational Diabetes
    View official trial listing →
  • Completed NCT NCT00577824

    Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)

    Not yet reported AstraZeneca 181 participants Est. completion 2008-11 12 sites
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT00579150

    Exenatide Pregnancy Registry - Type 2 Diabetes in Pregnancy

    AstraZeneca 7 participants Est. completion 2016-04 1 site
    Type 2 diabetes Other conditions: Birth Defects, Preterm Birth
    View official trial listing →
  • Completed NCT NCT00603239

    Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin

    Not yet reported AstraZeneca 165 participants Est. completion 2009-07 25 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00612794

    A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 Diabetes

    Not yet reported AstraZeneca 30 participants Est. completion 2008-05 4 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00622323

    Post Marketing Surveillance Study of Byetta ™ (Exenatide) Use Among Filipino Patients

    AstraZeneca 41 participants Est. completion 2009-09 3 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00623545

    Bioenergetic Alterations After Exenatide Administration

    Not yet reported University of Wisconsin, Madison 28 participants Est. completion 2010-04 1 site
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT00635492

    CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy

    AstraZeneca 2515 participants Est. completion 2011-12 96 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00637273

    A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)

    Not yet reported AstraZeneca 514 participants Est. completion 2009-07 62 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00641056

    Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)

    Not yet reported AstraZeneca 467 participants Est. completion 2009-11 75 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00642538

    A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus

    Not yet reported Mannkind Corporation 20 participants Est. completion 2008-09 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00650546

    Role of Exenatide in NASH-a Pilot Study

    Not yet reported, Not yet reported Indiana University 8 participants Est. completion 2010-08 3 sites
    MASLD
    View official trial listing →
  • Completed NCT NCT00658021

    Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

    Not yet reported AstraZeneca 122 participants Est. completion 2020-04-01 53 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00667732

    How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics

    Not yet reported Oregon Health and Science University 41 participants Est. completion 2010-04 3 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00672399

    Electrophysiological Effects of a Single 10 μg Dose of Exenatide on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects

    Not yet reported AstraZeneca 70 participants Est. completion 2008-07 2 sites
    Other conditions: Healthy Subjects
    View official trial listing →
  • Completed NCT NCT00676338

    Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

    Not yet reported AstraZeneca 820 participants Est. completion 2011-01 106 sites
    Type 2 diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT00679042

    Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol

    Not yet reported CellTrans Inc. 21 participants Est. completion 2026-06-14 1 site
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Terminated NCT NCT00701935

    Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin

    Not yet reported AstraZeneca 80 participants Est. completion 2012-01 17 sites
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT00707031

    GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

    Not yet reported Sanofi 639 participants Est. completion 2010-11 18 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00717457

    A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.

    Not yet reported Hoffmann-La Roche 1189 participants Est. completion 2011-03 216 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00729326

    Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione

    Not yet reported AstraZeneca 83 participants Est. completion 2009-10 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00736229

    Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients

    Not yet reported Saint Luke's Health System 40 participants Est. completion 2012-08 1 site
    Cardiovascular disease Other conditions: Hyperglycemia, Acute Coronary Syndromes
    View official trial listing →
  • Completed NCT NCT00744224

    PREDnisolone-induced Beta-cell Dysfunction Prevented by EXenatide

    Not yet reported Amsterdam UMC, location VUmc 8 participants Est. completion 2010-01 1 site
    Other conditions: Glucocorticoid-induced Glucometabolic Abnormalities, Glucocorticoid-induced Beta-cell Dysfunction
    View official trial listing →
  • Completed NCT NCT00747968

    The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET

    Not yet reported, Not yet reported University of Aarhus 8 participants Est. completion 2011-03 4 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00753896

    Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin

    Not yet reported AstraZeneca 134 participants Est. completion 2009-11 26 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00765817

    Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus

    Not yet reported AstraZeneca 261 participants Est. completion 2010-01 59 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00766857

    Effects of Exenatide in Type 2 Diabetic Patients With Congestive Heart Failure

    Not yet reported Amsterdam UMC, location VUmc 27 participants Est. completion 2012-12 1 site
    Type 2 diabetesHeart failure
    View official trial listing →
  • Completed NCT NCT00775684

    Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass

    Not yet reported University of Pennsylvania 47 participants Est. completion 2012-11 3 sites
    PrediabetesType 2 diabetes
    View official trial listing →
  • Completed NCT NCT00782418

    A Study to Compare Methodologies for Assessing Glucose-Dependent Insulin Secretion (0000-104)(COMPLETED)

    Not yet reported Merck Sharp & Dohme LLC 27 participants Est. completion 2009-03
    Other conditions: The Methodology Assessment of Glucose Dependent Insulin Secretion
    View official trial listing →
  • Terminated NCT NCT00799435

    Evaluating the Use of Exenatide in People With Type 2 Diabetes and Diastolic Heart Failure

    Not yet reported Baylor College of Medicine 2 participants Est. completion 2012-04 1 site
    Type 2 diabetesHeart failure
    View official trial listing →
  • Completed NCT NCT00803920

    Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes Taking Twice-Daily Exenatide or Once-Weekly Exenatide

    HealthPartners Institute 8 participants Est. completion 2008-02 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00806520

    Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control

    HealthPartners Institute 16 participants Est. completion 2011-08 5 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00835848

    Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI

    Not yet reported Rigshospitalet, Denmark 100 participants Est. completion 2015-05 1 site
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT00845182

    Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function

    Not yet reported The University of Texas Health Science Center at San Antonio 43 participants Est. completion 2010-07 1 site
    Type 2 diabetesPrediabetes Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT00845507

    Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults

    Not yet reported University of Cincinnati 54 participants Est. completion 2015-07 1 site
    Other conditions: Weight Gain
    View official trial listing →
  • Withdrawn NCT NCT00845559

    The Effects of Exenatide on Post-Meal Sugar Peaks and Vascular Health in Obese/Pre-Diabetic Young Adults

    Not yet reported Yale University
    PrediabetesCardiovascular disease Other conditions: Obesity, Insulin Resistance
    View official trial listing →
  • Completed NCT NCT00855439

    Evaluation of Exenatide in Patients With Diabetic Neuropathy

    Not yet reported University of Michigan 46 participants Est. completion 2014-05 1 site
    Type 2 diabetes Other conditions: Diabetic Peripheral Neuropathy
    View official trial listing →
  • Completed NCT NCT00856609

    The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects

    Not yet reported National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 150 participants Est. completion 2016-09-19 1 site
    Other conditions: Weight Loss, Obesity
    View official trial listing →
  • Completed NCT NCT00870194

    A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin

    Not yet reported AstraZeneca 255 participants Est. completion 2010-04 36 sites
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT00872378

    The Effects of Exenatide After Gastric Restriction

    Not yet reported, Not yet reported Advanced Specialty Care 28 participants Est. completion 2010-12 2 sites
    Other conditions: Morbid Obesity
    View official trial listing →
  • Completed NCT NCT00877890

    A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)

    Not yet reported AstraZeneca 254 participants Est. completion 2010-01 41 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00882050

    Intravenous Exenatide (Byetta) During Surgery

    Not yet reported, Not yet reported Thomas Jefferson University 104 participants Est. completion 2016-04 1 site
    Other conditions: Euglycemia, Hypoglycemia, Hyperglycemia
    View official trial listing →
  • Completed NCT NCT00886626

    GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children

    Not yet reported University of Minnesota 12 participants Est. completion 2011-02 1 site
    Other conditions: Obesity, Morbid
    View official trial listing →
  • Completed NCT NCT00894322

    A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension

    Not yet reported, Not yet reported AstraZeneca 65 participants Est. completion 2009-08 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00917267

    A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects

    Not yet reported AstraZeneca 691 participants Est. completion 2011-04 42 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00935532

    Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus

    Not yet reported AstraZeneca 427 participants Est. completion 2011-07 22 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00937079

    Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients

    University Hospital, Basel, Switzerland 30 participants Est. completion 2011-12 1 site
    Other conditions: Hyperinsulinism, Hypoglycemia, Insulinoma
    View official trial listing →
  • Completed NCT NCT00943917

    Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus

    Not yet reported Intarcia Therapeutics 155 participants Est. completion 2011-02 50 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00948168

    Effect of Exenatide on Glucose Homeostasis Determinants in Type 2 Diabetes

    Not yet reported Cliniques universitaires Saint-Luc- Université Catholique de Louvain 34 participants Est. completion 2009-07 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00950677

    The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes

    Not yet reported Baylor College of Medicine 16 participants Est. completion 2011-05 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00960661

    A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes

    Not yet reported AstraZeneca 1036 participants Est. completion 2012-08 95 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00964262

    A Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of Sustained Release(SR) Exenatide

    Not yet reported Peptron, Inc. 34 participants Est. completion 2010-10 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00971659

    Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 Diabetes

    Not yet reported Profil Institut für Stoffwechselforschung GmbH 48 participants Est. completion 2008-11 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00974272

    Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation

    Not yet reported Carl T. Hayden VA Medical Center 39 participants Est. completion 2008-11 1 site
    Type 2 diabetesPrediabetes
    View official trial listing →
  • Completed NCT NCT01003184

    Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes

    Not yet reported AstraZeneca 222 participants Est. completion 2011-12 34 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01006889

    Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

    Not yet reported University of Florida 24 participants Est. completion 2010-02 1 site
    MASLDType 2 diabetes
    View official trial listing →
  • Completed NCT NCT01021527

    A Study to Assess the Effects of Exenatide on Insulin Secretion Rates Using a Graded Infusion of Intravenous Glucose (0000-099)(COMPLETED)

    Not yet reported Merck Sharp & Dohme LLC 12 participants Est. completion 2008-04
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01029886

    Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes

    Not yet reported AstraZeneca 912 participants Est. completion 2011-04 108 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01046721

    Study Looking at Cardiovascular Effects of Exenatide, Its Blood Pressure Lowering Effect and Its Mechanisms

    Not yet reported University of Nottingham 8 participants Est. completion 2012-12 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01056549

    Exenatide (Byetta ®) Regulation of Intestinal and Hepatic Lipoprotein Particle Production in Humans

    Not yet reported University Health Network, Toronto 15 participants Est. completion 2011-09 1 site
    Other conditions: Hyperlipidemia
    View official trial listing →
  • Completed NCT NCT01060059

    Exenatide and Basal Insulins Use in the Real Setting: an Observational Study in Patients With Type 2 Diabetes

    AstraZeneca 888 participants Est. completion 2012-05 50 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01061775

    Effects of Exenatide on Hypothalamic Obesity

    Not yet reported, Not yet reported Children's Hospitals and Clinics of Minnesota 19 participants Est. completion 2019-03-15 2 sites
    Other conditions: Hypothalamic Obesity
    View official trial listing →
  • Completed NCT NCT01064687

    A Study in Participants With Type 2 Diabetes Mellitus

    Not yet reported Eli Lilly and Company 978 participants Est. completion 2012-05 89 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01076842

    Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment

    Not yet reported Novo Nordisk A/S 75 participants Est. completion 2011-04 2 sites
    Other conditions: Diabetes Type 2
    View official trial listing →
  • Completed NCT NCT01077323

    A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents

    AstraZeneca 363766 participants Est. completion 2008-03 1 site
    Type 2 diabetes Other conditions: Healthy Subjects (Treated With no Diabetes Therapies)
    View official trial listing →
  • Completed NCT NCT01089569

    Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine

    Not yet reported HealthPartners Institute 60 participants Est. completion 2013-05 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01093729

    A Study of HM11260C in Healthy Male Subject

    Not yet reported Hanmi Pharmaceutical Company Limited 41 participants Est. completion 2010-10
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01104701

    A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension

    Not yet reported AstraZeneca 121 participants Est. completion 2010-12 2 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01107717

    Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM

    Not yet reported The University of Texas Health Science Center at San Antonio 318 participants Est. completion 2023-02-03 1 site
    Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT01136798

    Impact of Exenatide on Sleep in Type 2 Diabetes

    Not yet reported University of Chicago 18 participants Est. completion 2016-09-01 2 sites
    Type 2 diabetes Other conditions: Sleep Disordered Breathing
    View official trial listing →
  • Status unknown NCT NCT01140893

    Effects of Exenatide on Glycemic Control and Weight in Continuous Subcutaneous Insulin Infusion (CSII) Type 2 Treated Patients With Type 2 Diabetes

    Not yet reported, Not yet reported University Hospital, Caen 110 participants 3 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01144338

    Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

    Not yet reported AstraZeneca 14752 participants Est. completion 2017-04-24 629 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01147627

    Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients

    Not yet reported Sun Yat-sen University 416 participants Est. completion 2012-12 25 sites
    Type 2 diabetes Other conditions: Newly Diagnosed
    View official trial listing →
  • Completed NCT NCT01154933

    Exeantide in Type 2 Diabetes on Insulin

    Not yet reported University at Buffalo 24 participants Est. completion 2011-11 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01156779

    Study to Evaluate Safety and PK/PD of DA-3091 in Healthy Male Subjects

    Not yet reported Dong-A Pharmaceutical Co., Ltd. 31 participants 1 site
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Status unknown NCT NCT01174810

    Exendin-4 as a Treatment for Parkinson's Disease - Pilot Study

    Not yet reported University College, London 40 participants Est. completion 2013-03 1 site
    Other conditions: Parkinson's Disease
    View official trial listing →
  • Completed NCT NCT01181986

    The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes

    Not yet reported Carl T. Hayden VA Medical Center 76 participants Est. completion 2012-12 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01208649

    Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH)

    Not yet reported Ruhr University of Bochum 13 participants Est. completion 2010-09 1 site
    MASLD
    View official trial listing →
  • Completed NCT NCT01235819

    Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus

    Not yet reported Command Hospital, India 20 participants Est. completion 2011-09 1 site
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT01237197

    Exenatide in Extreme Pediatric Obesity

    Not yet reported University of Minnesota 26 participants Est. completion 2012-10 2 sites
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT01237314

    The Impact of Food on Blood Sugar in People With Type 2 Diabetes

    HealthPartners Institute 46 participants Est. completion 2013-05 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT01254123

    Effect of Additional Treatment With EXenatide in Patients With an Acute Myocardial Infarction (the EXAMI Trial)

    Not yet reported Amsterdam UMC, location VUmc 40 participants 1 site
    Cardiovascular disease
    View official trial listing →
  • Terminated NCT NCT01255163

    A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease

    Not yet reported National Institute on Aging (NIA) 57 participants Est. completion 2016-11-18 1 site
    Other conditions: Alzheimer's Disease, Mild Cognitive Impairment
    View official trial listing →
  • Completed NCT NCT01269008

    Closed Loop System With Pramlintide Versus Exenatide

    Not yet reported Albert Einstein College of Medicine 13 participants Est. completion 2013-01 1 site
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT01269034

    New Onset Type 1 Diabetes: Role of Exenatide

    Not yet reported Albert Einstein College of Medicine 13 participants Est. completion 2017-01-31 1 site
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT01269047

    Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia

    Not yet reported Albert Einstein College of Medicine 37 participants Est. completion 2016-12 1 site
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Status unknown NCT NCT01270191

    The Effects of Short-Term Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients

    Not yet reported Taipei Veterans General Hospital, Taiwan 160 participants Est. completion 2015-12 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01281228

    The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and Diabetes

    Not yet reported Amsterdam UMC, location VUmc 48 participants Est. completion 2013-10 1 site
    Type 2 diabetes Other conditions: Diabetes Mellitus, Obesity
    View official trial listing →
  • Completed NCT NCT01297062

    A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects

    Not yet reported AstraZeneca 94 participants Est. completion 2011-05 2 sites
    Other conditions: Healthy Subjects
    View official trial listing →
  • Withdrawn NCT NCT01302327

    GLP Analogs for Diabetes in Wolfram Syndrome Patients

    Not yet reported Hadassah Medical Organization Est. completion 2013-03-01
    Other conditions: Diabetes Mellitus Associated With Genetic Syndrome, Wolfram Syndrome
    View official trial listing →
  • Status unknown NCT NCT01342042

    The Safety,Preliminary Pharmacodynamics and Pharmacokinetics Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus

    Not yet reported CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 36 participants Est. completion 2011-12 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01364584

    Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes

    Not yet reported University of Colorado, Denver 23 participants Est. completion 2014-12 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01373216

    Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary Bypass

    Not yet reported Charles University, Czech Republic 38 participants Est. completion 2014-12 1 site
    Cardiovascular disease Other conditions: Decreased Left Ventricular Function
    View official trial listing →
  • Terminated NCT NCT01381926

    Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist

    Not yet reported University of Alabama at Birmingham 14 participants Est. completion 2015-08 1 site
    Type 2 diabetes Other conditions: Bone Remodeling
    View official trial listing →
  • Completed NCT NCT01416649

    Impact of Exenatide on Sleep Duration

    University of Chicago 8 participants Est. completion 2021-04-21 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01429506

    Efficacy of Laparoscopic Sleeve Gastrectomy and Intensive Medical Management in Obese Type 2 Diabetes

    Not yet reported Post Graduate Institute of Medical Education and Research, Chandigarh 30 participants Est. completion 2012-08 1 site
    Other conditions: Diabetes Mellitus, Obesity
    View official trial listing →
  • Completed NCT NCT01432405

    Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes

    Not yet reported Baylor College of Medicine 24 participants Est. completion 2009-06 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT01435980

    Study of Comparison the Treatment Effect Between Gastric Bypass and Exenatide in Type 2 Diabetes

    Not yet reported Wu Qinan 60 participants Est. completion 2016-02 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01444898

    Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome

    Not yet reported Children's Hospital Los Angeles 10 participants Est. completion 2013-12 1 site
    Other conditions: Prader-Willi Syndrome
    View official trial listing →
  • Completed NCT NCT01452451

    Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

    Not yet reported Hanmi Pharmaceutical Company Limited 72 participants 1 site
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT01455857

    A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes

    Not yet reported Intarcia Therapeutics 460 participants Est. completion 2014-09 121 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01455870

    A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes

    Not yet reported Intarcia Therapeutics 535 participants Est. completion 2015-07 54 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Withdrawn NCT NCT01455883

    A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes

    Not yet reported Intarcia Therapeutics Est. completion 2014-07 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01455896

    A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650

    Not yet reported Intarcia Therapeutics 4156 participants Est. completion 2016-03 42 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Withdrawn NCT NCT01455909

    A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes

    Not yet reported Intarcia Therapeutics Est. completion 2014-07 1 site Added to GLP-1
    Type 2 diabetes
    View official trial listing →
  • Withdrawn NCT NCT01455922

    A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes

    Not yet reported Intarcia Therapeutics Est. completion 2014-07 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01473147

    Additional GLP-1 Analogue on CSII Treatment for Poorly Controlled Type 2 Diabetic Patients

    Not yet reported Chang Gung Memorial Hospital 51 participants Est. completion 2013-06 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01484873

    Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor

    Not yet reported Vanderbilt University Medical Center 10 participants Est. completion 2015-03 1 site
    Other conditions: Obesity, Overweight, Craniopharyngioma
    View official trial listing →
  • Completed NCT NCT01501084

    Effects of the GLP-1 Exenatide on Satiety in Lean and Obese Women

    Not yet reported University of California, Los Angeles 34 participants Est. completion 2013-02 1 site
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT01507038

    Safety and Efficacy of YH14617 in Diabetes Mellitus

    Not yet reported Yuhan Corporation 84 participants Est. completion 2015-02 1 site
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Enrolling by invitation NCT NCT01511393

    An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)

    Novo Nordisk A/S 6750 participants Est. completion 2039-12 1 site
    Type 2 diabetes Other conditions: Diabetes, Medullary Thyroid Carcinoma, Weight Management
    View official trial listing →
  • Terminated NCT NCT01514149

    Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy

    Not yet reported ConjuChem 73 participants Est. completion 2013-03 22 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01524705

    FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)

    Not yet reported University of Washington 102 participants Est. completion 2014-07 12 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01554618

    Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes

    Not yet reported AstraZeneca 84 participants Est. completion 2021-05-05 35 sites
    Type 2 diabetes
    View official trial listing →
  • Withdrawn NCT NCT01573806

    Pharmacology of Exenatide in Pediatric Sepsis

    Not yet reported, Not yet reported Seattle Children's Hospital Est. completion 2014-10 1 site
    Other conditions: Septic Shock, Inflammation, Glucose Homeostasis, Organ Dysfunction, Health-related Quality of Life
    View official trial listing →
  • Completed NCT NCT01575301

    DIabetes REsearCh on Patient sTratification (DIRECT): GLP-1R Agonists

    Not yet reported University of Dundee 411 participants Est. completion 2015-12-11 4 sites
    Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT01580514

    Myocardial Protection of Exenatide in AMI

    Not yet reported Kyunghee University Medical Center 127 participants Est. completion 2011-08 1 site
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT01588418

    Acute Effect of Exenatide on Brain Glucose Metabolism

    Not yet reported The University of Texas Health Science Center at San Antonio 15 participants Est. completion 2015-07 1 site
    Prediabetes Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT01590433

    Weight Loss With Exenatide Treatment

    Not yet reported Jody Dushay 249 participants Est. completion 2019-01 1 site
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT01602913

    Type II Diabetes Mellitus in Patients Exposed to Pravastatin and Paroxetine

    GlaxoSmithKline 1 participants Est. completion 2012-05
    Other conditions: Depression, Postpartum
    View official trial listing →
  • Completed NCT NCT01652716

    Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes

    Not yet reported AstraZeneca 377 participants Est. completion 2014-08 58 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01652729

    Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus

    Not yet reported AstraZeneca 365 participants Est. completion 2014-04 60 sites
    Other conditions: Diabetes Type 2
    View official trial listing →
  • Completed NCT NCT01664624

    Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes

    Not yet reported AstraZeneca 40 participants Est. completion 2012-11 2 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01676116

    The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy

    Not yet reported Novo Nordisk A/S 438 participants Est. completion 2014-03-11 109 sites
    Type 2 diabetes Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT01677104

    The Microvascular Function of GLP-1 and Its Analogues

    Not yet reported Katarina Kos 63 participants Est. completion 2014-07 1 site
    Type 2 diabetes Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT01687582

    Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients

    Not yet reported Cliniques universitaires Saint-Luc- Université Catholique de Louvain 10 participants Est. completion 2013-03 1 site
    Type 2 diabetes Other conditions: Psoriasis
    View official trial listing →
  • Completed NCT NCT01700075

    Physical and Chemical Study of Atherosclerosis Mechanisms

    Not yet reported Nazarbayev University 97 participants Est. completion 2011-12 1 site
    Cardiovascular diseaseType 2 diabetes Other conditions: Atherosclerosis of Femoral Artery
    View official trial listing →
  • Completed NCT NCT01724060

    Effects of Obesity Treatments on Food Preferences and Metabolism

    Imperial College London 80 participants Est. completion 2017-10 2 sites
    Type 2 diabetes Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT01744236

    SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies

    Not yet reported Amsterdam UMC, location VUmc 70 participants Est. completion 2015-08 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01767389

    Glucagon-like Peptide (GLP) Utilization and Safety

    GlaxoSmithKline 1 participants Est. completion 2013-12
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01776788

    Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients

    Not yet reported The First Affiliated Hospital of Xiamen University 156 participants Est. completion 2015-02 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT01783717

    Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage

    Not yet reported Huashan Hospital 10 participants Est. completion 2015-07 1 site
    Other conditions: Hypothalamic Obesity, Diabetes Mellitus
    View official trial listing →
  • Terminated NCT NCT01785771

    A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c

    Not yet reported Intarcia Therapeutics 100 participants Est. completion 2018-01 51 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01789957

    Extension Study for 2993-112

    Not yet reported AstraZeneca 225 participants Est. completion 2004-06 226 sites
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT01791465

    Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults

    Not yet reported Vanderbilt University 6 participants Est. completion 2014-12 1 site
    Other conditions: Human Immunodeficiency Virus Infection, Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT01794429

    Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue

    Not yet reported Bjorn H. Ebdrup 45 participants Est. completion 2015-06 1 site
    Metabolic syndrome Other conditions: Obesity, Drug-induced Obesity, Schizophrenia
    View official trial listing →
  • Completed NCT NCT01798264

    Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 Diabetes

    Not yet reported Intarcia Therapeutics 44 participants Est. completion 2009-05 3 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01817569

    Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)

    AstraZeneca 2948 participants Est. completion 2019-10-03 46 sites
    Type 2 diabetes
    View official trial listing →
  • Withdrawn NCT NCT01818648

    Exenatide on GI Motor Function and Permeability in Short Bowel Syndrome

    Not yet reported Mayo Clinic Est. completion 2014-01
    Other conditions: Short Bowel Syndrome
    View official trial listing →
  • Completed NCT NCT01825148

    GLP-1 Receptor Targeting in Diabetic and Healthy Individuals

    Radboud University Medical Center 20 participants Est. completion 2014-05 1 site
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT01843127

    A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.

    Not yet reported Gilead Sciences 24 participants Est. completion 2013-09 3 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01855490

    Study of the Acute Metabolic Effect of Exenatide in Type 1 Diabetes

    Not yet reported Yale University 17 participants Est. completion 2013-10 1 site
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT01857895

    Feasibility Study of Exenatide by Continuous Subcutaneous Infusion

    Not yet reported GlaxoSmithKline 10 participants Est. completion 2013-11-01 1 site
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT01876849

    An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus

    Not yet reported AstraZeneca 275 participants Est. completion 2008-07 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01885208

    Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

    Not yet reported Novo Nordisk A/S 813 participants Est. completion 2015-07-13 146 sites
    Type 2 diabetes Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT01928329

    A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes

    Not yet reported Yale University 79 participants Est. completion 2019-08 8 sites
    Other conditions: Type I Diabetes
    View official trial listing →
  • Terminated NCT NCT01934816

    Incretin and KATP Channels

    Not yet reported Katarina Kos 2 participants Est. completion 2015-10 1 site
    Other conditions: Healthy Subjects
    View official trial listing →
  • Status unknown NCT NCT01938235

    Exenatide for Myocardial Protection During Reperfusion Study

    Not yet reported University Health Network, Toronto 198 participants Est. completion 2018-01 10 sites
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT01940770

    Specific Clinical Experience Investigation for Long-term Use of Bydureon.

    AstraZeneca 1137 participants Est. completion 2019-11-29 47 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01951651

    Effect of Exenatide on Liver and Heart Fat and Inflammation

    Not yet reported Baylor College of Medicine 24 participants Est. completion 2013-03 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01969149

    Exenatide for Stress Hyperglycemia

    Not yet reported, Not yet reported Centre Hospitalier Universitaire de Besancon 110 participants Est. completion 2016-12 1 site
    Other conditions: Stress Hyperglycemia
    View official trial listing →
  • Completed NCT NCT01971242

    Trial of Exenatide for Parkinson's Disease

    Not yet reported University College, London 60 participants Est. completion 2016-08 1 site
    Other conditions: Parkinson's Disease
    View official trial listing →
  • Status unknown NCT NCT01988545

    GLP-1's Effect on Cardiac Parameters and Mesenteric Blood Flow

    Not yet reported Zealand University Hospital 8 participants Est. completion 2014-12 1 site
    Other conditions: Healthy
    View official trial listing →
  • Terminated NCT NCT02020616

    A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 Diabetes

    Not yet reported, Not yet reported Eli Lilly and Company 60 participants Est. completion 2015-02 5 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02042664

    Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics

    Not yet reported Assistance Publique Hopitaux De Marseille 44 participants Est. completion 2015-06 1 site
    Other conditions: Obesity, Diabetes
    View official trial listing →
  • Completed NCT NCT02057172

    Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

    Not yet reported Hanmi Pharmaceutical Company Limited 254 participants Est. completion 2014-12 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02058940

    Intravenous Exenatide in Patients With Acute Brain Injury

    Not yet reported University of North Carolina, Chapel Hill 8 participants Est. completion 2017-08 1 site
    Other conditions: Brain Injuries
    View official trial listing →
  • Status unknown NCT NCT02059564

    A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

    Not yet reported Hanmi Pharmaceutical Company Limited 44 participants Est. completion 2014-12 1 site
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Terminated NCT NCT02072096

    A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)

    Not yet reported Eli Lilly and Company 192 participants Est. completion 2015-10 34 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02081118

    Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

    Not yet reported Hanmi Pharmaceutical Company Limited 209 participants Est. completion 2015-04 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02084251

    Clinical Trial for PB-119 in Healthy Subjects (Phase I)

    Not yet reported PegBio Co., Ltd. 70 participants Est. completion 2014-11 1 site
    Other conditions: Type II Diabetes
    View official trial listing →
  • Completed NCT NCT02084654

    Exenatide and Weight Loss for Diabetes Prevention

    Not yet reported Stanford University 66 participants Est. completion 2013-02
    Other conditions: Pre Diabetes, Insulin Resistance
    View official trial listing →
  • Completed NCT NCT02090673

    Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea

    AstraZeneca 1711 participants Est. completion 2014-03 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02092597

    Safety Evaluation of Adverse Reactions in Diabetes

    Not yet reported Charles University, Czech Republic 42 participants Est. completion 2016-09 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02104739

    Effects of Antidiabetic Medications on the Postprandial State in Prediabetes

    Not yet reported The University of Texas Health Science Center, Houston 21 participants Est. completion 2017-03 1 site
    Prediabetes Other conditions: Obesity
    View official trial listing →
  • Status unknown NCT NCT02118376

    Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory Status

    Not yet reported Shanghai 10th People's Hospital 20 participants Est. completion 2014-12 1 site
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT02119819

    A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes

    Not yet reported OPKO Health, Inc. 420 participants Est. completion 2015-10 51 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02127541

    New Imaging Procedure for the Localisation of Insulinoma

    Not yet reported University Hospital, Basel, Switzerland 52 participants Est. completion 2017-11 1 site
    Other conditions: Endogenous Hyperinsulinaemic Hypoglycaemia
    View official trial listing →
  • Status unknown NCT NCT02129985

    Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy

    Not yet reported xiaolong zhao 100 participants Est. completion 2015-09 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02150707

    The Differential Effects of Diabetes Therapy on Inflammation

    University College Dublin 17 participants Est. completion 2015-12 1 site
    Chronic kidney diseaseType 2 diabetes
    View official trial listing →
  • Completed NCT NCT02157974

    Liver and Fat Regulation in Overweight Adolescent Girls

    Not yet reported, Not yet reported University of Colorado, Denver 92 participants Est. completion 2022-12 1 site
    Other conditions: Hepatic Steatosis, Polycystic Ovarian Syndrome, Obesity
    View official trial listing →
  • Completed NCT NCT02160990

    Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying

    Not yet reported Mayo Clinic 20 participants Est. completion 2015-03 1 site
    Other conditions: Obesity
    View official trial listing →
  • Status unknown NCT NCT02162550

    Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus

    Not yet reported Phoenix VA Health Care System 148 participants Est. completion 2019-09 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02170324

    GLP-1 Agonism Stimulates Browning of Subcutaneous White Adipose Tissue in Obesity Men

    Not yet reported Xiang Guang-da 20 participants Est. completion 2015-07 1 site
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT02194595

    Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)

    Not yet reported Mount Sinai Hospital, Canada 105 participants Est. completion 2022-02 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02229383

    Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus

    Not yet reported AstraZeneca 464 participants Est. completion 2016-08-29 123 sites
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT02229396

    Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo

    Not yet reported AstraZeneca 695 participants Est. completion 2017-12-28 133 sites
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Terminated NCT NCT02244164

    Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.

    Not yet reported Erasme University Hospital 5 participants Est. completion 2023-02-13 1 site
    Type 2 diabetes Other conditions: Incretinomimetics, Pancreas
    View official trial listing →
  • Completed NCT NCT02251431

    Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome

    Not yet reported Baylor Research Institute 57 participants Est. completion 2019-12 1 site
    Type 2 diabetesChronic kidney disease Other conditions: Left Ventricular Diastolic Dysfunction
    View official trial listing →
  • Completed NCT NCT02288273

    Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.

    Not yet reported AstraZeneca 239 participants Est. completion 2015-08 29 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02302976

    GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration

    Not yet reported Yale University 13 participants Est. completion 2018-08-01 1 site
    Other conditions: Cocaine Dependence
    View official trial listing →
  • Completed NCT NCT02303730

    Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes

    Not yet reported Fudan University 76 participants Est. completion 2017-11 5 sites
    Type 2 diabetes Other conditions: Non-alcoholic Fatty Liver Disease
    View official trial listing →
  • Completed NCT NCT02313220

    Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body Weight

    Not yet reported Uppsala University 50 participants Est. completion 2016-03 1 site
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT02320045

    Study to Evaluate Pharmacokinetics of ITCA 650 in Subjects With Renal Impairment Compared to Normal Subjects

    Not yet reported Intarcia Therapeutics 38 participants Est. completion 2015-07 4 sites Stand-alone
    Other conditions: Renal Insufficiency
    View official trial listing →
  • Completed NCT NCT02325960

    A Comparison of Exenatide and Insulin Glargine

    Not yet reported The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 44 participants Est. completion 2016-10 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT02344641

    Efficacy and Mechanism of Exenatide on Improving Heart Function in Type 2 Diabetes With Heart Failure Patients

    Not yet reported Chinese Academy of Medical Sciences, Fuwai Hospital 234 participants Est. completion 2016-12
    Type 2 diabetesHeart failure
    View official trial listing →
  • Completed NCT NCT02349802

    Autoinjector Device Assessment Study

    Not yet reported AstraZeneca 3052 participants Est. completion 2013-12 2 sites
    Other conditions: Healthy Subjects
    View official trial listing →
  • Completed NCT NCT02380521

    Exenatide Once Weekly, Cardiovascular Risk and Type-2 Diabetes

    Not yet reported University of Palermo 60 participants Est. completion 2016-11 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02404376

    COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial

    Not yet reported Hospital Universitari Vall d'Hebron Research Institute 378 participants Est. completion 2020-06 6 sites
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT02417142

    Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia

    Not yet reported University of Massachusetts, Worcester 70 participants Est. completion 2020-07 1 site
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT02432976

    Impact of Perioperative Exenatide Infusion on Quality of Life in Cardiac Surgery Patients

    Not yet reported, Not yet reported Centre Hospitalier Universitaire de Besancon 64 participants Est. completion 2017-01 1 site
    Other conditions: Quality of Life
    View official trial listing →
  • Completed NCT NCT02442791

    GLP-1 Analogs for Neuroprotection After Cardiac Arrest

    Not yet reported Jesper Kjaergaard 120 participants Est. completion 2016-06 1 site
    Other conditions: Cardiac Arrest, Coma
    View official trial listing →
  • Completed NCT NCT02449603

    Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes

    Not yet reported Xijing Hospital 150 participants Est. completion 2018-04 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02455076

    Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes

    Not yet reported Emory University 150 participants Est. completion 2018-03 2 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02456428

    Incretin-based Drugs and the Risk of Heart Failure

    Canadian Network for Observational Drug Effect Studies, CNODES 1499650 participants Est. completion 2015-05 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02467920

    Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM

    Not yet reported Huazhong University of Science and Technology 349 participants Est. completion 2017-12 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02475499

    Incretin-based Drugs and Pancreatic Cancer

    Canadian Network for Observational Drug Effect Studies, CNODES 886172 participants Est. completion 2015-04 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02476760

    Incretin-based Drugs and Acute Pancreatitis

    Canadian Network for Observational Drug Effect Studies, CNODES 1417914 participants Est. completion 2015-04 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02496611

    Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe Obesity

    Not yet reported University of Minnesota 100 participants Est. completion 2020-08-14 1 site
    Other conditions: Severe Obesity
    View official trial listing →
  • Status unknown NCT NCT02501850

    The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)

    Not yet reported Hospital Universitari Vall d'Hebron Research Institute 40 participants Est. completion 2015-10 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02533453

    A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.

    Not yet reported AstraZeneca 110 participants Est. completion 2016-12-07 15 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02541734

    Effect of Gelofusine on GLP1-receptor Imaging

    Not yet reported, Not yet reported Radboud University Medical Center 12 participants Est. completion 2017-05
    Other conditions: Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus
    View official trial listing →
  • Status unknown NCT NCT02560376

    68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis

    Not yet reported Peking Union Medical College Hospital 100 participants Est. completion 2016-12 1 site
    Other conditions: Insulinoma, Nesidioblastosis
    View official trial listing →
  • Status unknown NCT NCT02584075

    Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial Function

    Not yet reported Beijing Chao Yang Hospital 100 participants Est. completion 2018-01
    Other conditions: Coronary Endothelial Function
    View official trial listing →
  • Status unknown NCT NCT02584582

    The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate

    Not yet reported, Not yet reported Hvidovre University Hospital 10 participants
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Withdrawn NCT NCT02586831

    Diabetes Islet Preservation Immune Treatment

    Not yet reported, Not yet reported Camillo Ricordi and Jay Skyler Est. completion 2024-06-01
    Other conditions: Diabetes Mellitus, Type 1, Hypoglycemia, Autoimmune Diseases, Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT02621489

    Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes Subjects

    Not yet reported Karolinska Institutet 38 participants Est. completion 2022-10 1 site
    Other conditions: Atherosclerosis, Diabetes, Restenosis
    View official trial listing →
  • Completed NCT NCT02635386

    EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)

    Not yet reported Woman's 119 participants Est. completion 2020-10-09 1 site
    Other conditions: Polycystic Ovary Syndrome, Obesity
    View official trial listing →
  • Completed NCT NCT02638805

    Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide

    Not yet reported Intarcia Therapeutics 136 participants Est. completion 2017-10 36 sites Added to GLP-1
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02641899

    Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied Drugs

    Not yet reported Intarcia Therapeutics 33 participants Est. completion 2016-03 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT02641990

    Study of the Effect of ITCA 650 on the PK/PD of Oral Contraceptive in Healthy Female Subjects

    Not yet reported Intarcia Therapeutics 28 participants Est. completion 2016-02 2 sites Stand-alone
    Other conditions: Healthy Adult Premenopausal Female Volunteers
    View official trial listing →
  • Completed NCT NCT02650479

    Study of the Effects of Intravenous Exenatide on Cardiac Repolarization

    Not yet reported Intarcia Therapeutics 82 participants Est. completion 2016-04 1 site
    Other conditions: Healthy Adult Male and Female Volunteers
    View official trial listing →
  • Completed NCT NCT02664441

    Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity

    Not yet reported Seattle Children's Hospital 42 participants Est. completion 2020-07-31 3 sites
    Other conditions: Hypothalamic Obesity
    View official trial listing →
  • Status unknown NCT NCT02673931

    GLP-1 and Hyperoxia for Organ Protection in Heart Surgery

    Not yet reported Rigshospitalet, Denmark 1400 participants Est. completion 2024-09 1 site
    Cardiovascular disease Other conditions: Coronary Disease, Shock, Cardiogenic, Renal Failure, Brain Injury, Aortic Valve Disease
    View official trial listing →
  • Completed NCT NCT02685852

    Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia

    Not yet reported University of Minnesota 11 participants Est. completion 2019-07-22 1 site Stand-alone
    Other conditions: Hyperinsulinemic Hypoglycemia
    View official trial listing →
  • Completed NCT NCT02690883

    Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy

    Not yet reported Nanfang Hospital, Southern Medical University 92 participants Est. completion 2019-12-30
    Other conditions: Diabetic Nephropathies
    View official trial listing →
  • Status unknown NCT NCT02690987

    Gut Hormones in Obesity, Nicotine and Alcohol Dependence

    Not yet reported Imperial College London 95 participants Est. completion 2020-08 1 site
    Other conditions: Obesity, Smoking Cessation, Alcoholism
    View official trial listing →
  • Completed NCT NCT02735031

    Exenatide and Impaired Hypoglycaemic Awareness in Type 1 Diabetes

    Not yet reported, Not yet reported Radboud University Medical Center 10 participants Est. completion 2018-04-09 1 site
    Other conditions: Diabetes Mellitus, Type 1, Hypoglycemia
    View official trial listing →
  • Completed NCT NCT02787551

    Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

    Not yet reported Sanofi 514 participants Est. completion 2018-11-17 124 sites Added to GLP-1
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT02793154

    An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects

    Not yet reported GlaxoSmithKline 4 participants Est. completion 2017-03-16 2 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02794402

    Double-blinded, 6 Months Study With Bydureon® or Placebo in Adolescents With Obesity to Explore Changes in BMI

    Not yet reported Uppsala University 44 participants Est. completion 2016-11 2 sites
    Other conditions: Obesity
    View official trial listing →
  • Terminated NCT NCT02802514

    A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects

    Not yet reported GlaxoSmithKline 5 participants Est. completion 2017-09-07 1 site
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Withdrawn NCT NCT02811484

    Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes

    Not yet reported Weill Medical College of Cornell University Est. completion 2018-12 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT02829502

    The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke

    Not yet reported Christina Kruuse 30 participants Est. completion 2023-11 1 site
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT02838589

    The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Non-stroke Volunteers

    Not yet reported Christina Kruuse 30 participants Est. completion 2017-02 1 site
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT02843399

    Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy

    AstraZeneca 15498 participants Est. completion 2016-12-15 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT02847403

    Long-acting Exenatide and Cognitive Decline in Dysglycemic Patients

    Not yet reported Azienda Ospedaliero-Universitaria di Parma 40 participants Est. completion 2021-10-31 2 sites
    Other conditions: Dysglycemia, Cognitive Deficit
    View official trial listing →
  • Completed NCT NCT02860923

    Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy

    Not yet reported University Hospital, Bordeaux 42 participants Est. completion 2018-09-30 11 sites
    Other conditions: Craniopharyngiomas, Hypothalamic Obesity
    View official trial listing →
  • Status unknown NCT NCT02887625

    Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM

    Not yet reported Dr. Muhammad Abdulghani 410 participants Est. completion 2017-05 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02895672

    GLP-1/Basal Insulin Combination Therapy

    Albany College of Pharmacy and Health Sciences 150 participants Est. completion 2016-12
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02917057

    Subanalyses of Elderly Type 2 Diabetes Patients or Type 2 Diabetes Patients With Renal Impairment

    AstraZeneca 6024 participants Est. completion 2015-08-01 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02962492

    An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes

    Not yet reported University at Buffalo 70 participants Est. completion 2021-10-24 1 site
    Other conditions: Evaluate Ketogenic Stress
    View official trial listing →
  • Completed NCT NCT02974244

    Comparison of the Effectiveness and Tolerability of Exenatide Once-weekly Compared to Basal Insulins

    AstraZeneca 7000 participants Est. completion 2014-10-28 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02975297

    Exenatide Once Weekly for Smoking Cessation

    Not yet reported, Not yet reported The University of Texas Health Science Center, Houston 84 participants Est. completion 2020-01-03 1 site
    Other conditions: Smoking Cessation
    View official trial listing →
  • Completed NCT NCT02981069

    Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM

    Not yet reported The University of Texas Health Science Center at San Antonio 90 participants Est. completion 2023-03-19 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02987348

    Clinical Outcomes of Exenatide Versus Basal Insulin

    AstraZeneca 18000 participants Est. completion 2015-06-30 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT03002675

    Exenatide and Brown Adipose Tissue

    Not yet reported Ingrid Jazet 24 participants 1 site
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT03007329

    Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus.

    Not yet reported Medical University of Vienna 34 participants Est. completion 2020-01-16 1 site
    Type 2 diabetes Other conditions: Steatosis, Liver
    View official trial listing →
  • Completed NCT NCT03017352

    Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetic Cases

    Not yet reported Filip Krag Knop 108 participants Est. completion 2019-06 1 site
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Status unknown NCT NCT03018665

    A Study of the Effect of Glucagon-like Peptide 1(GLP-1) Receptor Agonist in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese

    Not yet reported The First Hospital of Jilin University 200 participants 1 site
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT03029351

    GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes

    Not yet reported University at Buffalo 15 participants Est. completion 2019-07 1 site
    Type 2 diabetes Other conditions: Kidney Diseases
    View official trial listing →
  • Completed NCT NCT03059719

    Clinical Trial for PB-119 in Subjects With Type 2 Diabetes Mellitus

    Not yet reported PegBio Co., Ltd. 36 participants Est. completion 2016-10-27 1 site
    Other conditions: Type II Diabetes Mellitus
    View official trial listing →
  • Terminated NCT NCT03060980

    Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin

    Not yet reported Intarcia Therapeutics 245 participants Est. completion 2018-01-26 101 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03151005

    The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS

    Not yet reported Xinqiao Hospital of Chongqing 70 participants Est. completion 2021-04-23 1 site
    Other conditions: Polycystic Ovary Syndrome (PCOS), Overweight, Obesity
    View official trial listing →
  • Completed NCT NCT03160261

    Effect of Exenatide on Cortisol Secretion

    Not yet reported University of Tartu 10 participants Est. completion 2017-12-28 1 site
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT03167411

    Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection

    Not yet reported Theracos 20 participants Est. completion 2017-06-29 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT03182192

    GLP1R-imaging in Hypoglycemia

    Not yet reported Radboud University Medical Center 12 participants Est. completion 2024-07-01 2 sites
    Other conditions: Hypoglycemia
    View official trial listing →
  • Status unknown NCT NCT03182231

    GLP1-imaging Before and After Bariatric Surgery

    Not yet reported, Not yet reported Radboud University Medical Center 12 participants Est. completion 2023-07-01 2 sites
    Type 2 diabetes Other conditions: Bariatric Surgery Candidate
    View official trial listing →
  • Status unknown NCT NCT03182296

    Visualizing Beta Cells in Patients With a History of Gestational Diabetes

    Not yet reported Radboud University Medical Center 24 participants Est. completion 2026-01-01 1 site
    Other conditions: Gestational Diabetes
    View official trial listing →
  • Completed NCT NCT03189953

    68Ga-NODAGA-exendin-4 PET/CT for Diagnostic Imaging in AHH

    Not yet reported, Not yet reported Radboud University Medical Center 56 participants Est. completion 2021-05
    Other conditions: Insulinoma
    View official trial listing →
  • Completed NCT NCT03199261

    A Study of Pharmacokinetic Comparison of Two Recombinant Exendin-4 Formulations in Chinese Healthy Male Subjects

    Not yet reported CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 24 participants Est. completion 2017-01-21 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03232112

    Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?

    Not yet reported Anders Fink-Jensen, MD, DMSci 152 participants Est. completion 2020-10-05 1 site
    Alcohol use disorder Other conditions: Addiction, Alcohol
    View official trial listing →
  • Status unknown NCT NCT03239119

    The Effectivity and Safety Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus

    Not yet reported CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 456 participants Est. completion 2019-01-15
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT03287076

    Trial of EXenatide in Acute Ischaemic Stroke

    Not yet reported Neuroscience Trials Australia 350 participants Est. completion 2021-12-31 15 sites
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT03297879

    Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients With Newly Diagnosed Type 2 Diabetes

    Not yet reported Beijing Chao Yang Hospital 230 participants Est. completion 2016-02-28
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03331289

    Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria

    Not yet reported The University of Texas Health Science Center at San Antonio 107 participants Est. completion 2022-11-04 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03350191

    A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus Patients

    Not yet reported Sanofi 13 participants Est. completion 2018-06-07 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03352869

    Research of Exenatide for Overweight/Obese PCOS Patients With IGR

    Not yet reported RenJi Hospital 183 participants Est. completion 2018-07-31 1 site
    Other conditions: Polycystic Ovary Syndrome, Overweight and Obesity, Disorder of Glucose Regulation
    View official trial listing →
  • Completed NCT NCT03361098

    DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2

    Not yet reported Amsterdam UMC, location VUmc 65 participants Est. completion 2020-03-25 1 site
    Type 2 diabetes Other conditions: Obesity
    View official trial listing →
  • Status unknown NCT NCT03383068

    Research of Intensive Metabolic Intervention Before Pregnancy in PCOS

    Not yet reported RenJi Hospital 160 participants Est. completion 2020-06-30 1 site
    Prediabetes Other conditions: PCOS
    View official trial listing →
  • Terminated NCT NCT03419624

    The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients

    Not yet reported Universitätsklinikum Hamburg-Eppendorf 13 participants Est. completion 2019-08-05 4 sites
    Type 2 diabetes Other conditions: Obesity
    View official trial listing →
  • Status unknown NCT NCT03444142

    Effect of Exenatide LAR or Dulaglutide on the Variability of 24-hour Heart Rate and Blood Pressure in Type 2 Diabetes

    Not yet reported University of Guadalajara 30 participants Est. completion 2021-11-30 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03456687

    Effects of Exenatide on Motor Function and the Brain

    Not yet reported University of Florida 5 participants Est. completion 2021-08-25 1 site
    Other conditions: Parkinson's Disease
    View official trial listing →
  • Completed NCT NCT03492580

    A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

    Janssen Research & Development, LLC 714582 participants Est. completion 2018-06-25 1 site
    Type 2 diabetesCardiovascular disease
    View official trial listing →
  • Terminated NCT NCT03645408

    The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers

    Not yet reported Boston Medical Center 8 participants Est. completion 2021-07-01 1 site
    Alcohol use disorder
    View official trial listing →
  • Status unknown NCT NCT03671733

    Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients

    Not yet reported Xiangya Hospital of Central South University 150 participants Est. completion 2022-09-01 1 site
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT03672604

    A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects

    Not yet reported Neuraly, Inc. 96 participants Est. completion 2019-07-30 1 site
    Other conditions: Safety and Tolerability in Healthy Volunteers
    View official trial listing →
  • Status unknown NCT NCT03768518

    GLP-1 Receptor Expression in CHI

    Radboud University Medical Center 40 participants Est. completion 2019-02-01 1 site
    Other conditions: Congenital Hyperinsulinism
    View official trial listing →
  • Status unknown NCT NCT03804411

    Prognostic Predictors of Response to Hypoglycemic Therapy

    Not yet reported Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health 800 participants Est. completion 2020-05 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03835013

    Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male Volunteers

    Not yet reported Cambridge University Hospitals NHS Foundation Trust 26 participants Est. completion 2021-11-01 1 site
    Cardiovascular disease
    View official trial listing →
  • Terminated NCT NCT03889496

    Quantitative GLP-1 Receptor Imaging Correlated to ex Vivo Distribution of In-111-exendin

    Not yet reported Radboud University Medical Center 12 participants Est. completion 2021-06-14 1 site
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT03923114

    Imaging Pituitary ActiVation by Exendin

    Not yet reported Radboud University Medical Center 20 participants Est. completion 2024-04-03 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT03959865

    GLP-1 REceptor Agonists and Real World EvIdeNce

    University of Padova 6000 participants Est. completion 2019-05-31 6 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03961256

    Assess the Efficacy and Safety of Exenatide SR for the Prevention of Diabetes After Kidney Transplantation

    Not yet reported Mayo Clinic 9 participants Est. completion 2021-10-18 1 site
    Other conditions: Pre Diabetes
    View official trial listing →
  • Completed NCT NCT03970044

    Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.

    Not yet reported Consano Clinical Research, LLC 67 participants Est. completion 2021-06-01 1 site
    Type 2 diabetes
    View official trial listing →
  • Withdrawn NCT NCT04001231

    Study of Exenatide Once-Weekly Suspension in Chinese Patients With Type 2 Diabetes Mellitus

    Not yet reported AstraZeneca Est. completion 2021-07-02
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT04027023

    Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus

    Not yet reported Sciema UG 9 participants Est. completion 2021-05-31 2 sites
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT04029272

    Metformin vs Metformin Combined With GLP-1RA (Glucagon-like Peptide 1 Receptor Agonist) on Overweight/Obese PCOS Patients

    Not yet reported Peking Union Medical College Hospital 80 participants Est. completion 2020-12-31 1 site
    Other conditions: Polycystic Ovary Syndrome
    View official trial listing →
  • Completed NCT NCT04154072

    A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease

    Not yet reported Neuraly, Inc. 255 participants Est. completion 2023-02-14 61 sites
    Other conditions: Parkinson Disease
    View official trial listing →
  • Completed NCT NCT04159766

    A Study With NLY01 in Subjects With Type 2 Diabetes

    Not yet reported Neuraly, Inc. 20 participants Est. completion 2020-12-04 2 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04184947

    Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists

    University of Padova 10000 participants Est. completion 2020-02-29 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT04185350

    Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma

    Not yet reported Nanjing First Hospital, Nanjing Medical University 60 participants Est. completion 2020-05-05 1 site
    Other conditions: Insulinoma
    View official trial listing →
  • Completed NCT NCT04232969

    Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease

    Not yet reported University College, London 194 participants Est. completion 2024-07-31 1 site
    Other conditions: Parkinson's Disease
    View official trial listing →
  • Status unknown NCT NCT04269642

    SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease

    Not yet reported Peptron, Inc. 99 participants Est. completion 2021-12-31 5 sites
    Other conditions: Early Parkinson's Disease
    View official trial listing →
  • Completed NCT NCT04303819

    The Effect of Exenatide on Fasting Bile Acids

    Beijing Chao Yang Hospital 38 participants Est. completion 2020-01-31 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT04305002

    Exenatide Treatment in Parkinson's Disease

    Not yet reported Center for Neurology, Stockholm 60 participants Est. completion 2023-10-10 1 site
    Other conditions: Parkinson Disease
    View official trial listing →
  • Completed NCT NCT04307797

    Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes

    Not yet reported Cambridge University Hospitals NHS Foundation Trust 10 participants Est. completion 2022-10-07 1 site
    Type 2 diabetes Other conditions: Obesity
    View official trial listing →
  • Status unknown NCT NCT04379856

    Proof of Concept Study in Patients With Short Bowel Syndrome

    Not yet reported, Not yet reported 9 Meters Biopharma, Inc. 12 participants Est. completion 2020-12-31 1 site
    Other conditions: Short Bowel Syndrome
    View official trial listing →
  • Completed NCT NCT04431713

    Exenatide Once-weekly as a Treatment for Multiple System Atrophy

    Not yet reported University College, London 50 participants Est. completion 2024-03-22 1 site
    Other conditions: Multiple System Atrophy
    View official trial listing →
  • Completed NCT NCT04504370

    Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects

    Not yet reported PegBio Co., Ltd. 273 participants Est. completion 2022-11-28 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04504396

    Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy

    Not yet reported PegBio Co., Ltd. 620 participants Est. completion 2023-05-26 1 site
    Type 2 diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT04520490

    Brain Activation and Satiety in Children 2

    Not yet reported Seattle Children's Hospital 63 participants Est. completion 2026-02-12 1 site
    Other conditions: Childhood Obesity
    View official trial listing →
  • Status unknown NCT NCT04615910

    A GLP-1 Receptor PET Imaging Substudy Within the VER-A-T1D Trial Investigating the Effects on Beta Cell Mass

    Not yet reported Radboud University Medical Center 30 participants Est. completion 2025-07-01 2 sites
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Status unknown NCT NCT04733508

    Glucagon Like Peptide 1 Receptor (GLP1R) Expression and Beta-cell Mass in Patients With Type 2 Diabetes

    Not yet reported Radboud University Medical Center 28 participants Est. completion 2022-12-01 1 site
    Type 2 diabetes Other conditions: Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT04897802

    Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)

    Not yet reported Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau 42 participants Est. completion 2024-12-31 1 site
    Other conditions: Hypopituitarism, Central Diabetes Insipidus, Panhypopituitarism, Psychological Disorder, Social Isolation, Hypothalamic Diseases, Pituitary Diseases, Oxytocin Deficiency
    View official trial listing →
  • Completed NCT NCT04909333

    Exenatide-test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia

    Not yet reported University Hospital, Basel, Switzerland 29 participants Est. completion 2024-04-30 1 site
    Other conditions: Endogenous Hyperinsulinism
    View official trial listing →
  • Completed NCT NCT04941521

    Exenatide for Treating Cocaine Use Disorder

    Not yet reported, Not yet reported The University of Texas Health Science Center, Houston 3 participants Est. completion 2021-11-17 1 site
    Other conditions: Cocaine Use Disorder
    View official trial listing →
  • Completed NCT NCT04969627

    Effects of GLP-1 Analogue Combined With Metformin and Metformin on Gonadal and Metabolic Profiles in Chinese Overweight/Obese PCOS Patients With Hyperandrogenemia.

    Not yet reported Bing He 60 participants Est. completion 2022-03-29 1 site
    Other conditions: Polycystic Ovary Syndrome
    View official trial listing →
  • Status unknown NCT NCT04979611

    The Clinical Application of 68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma

    Not yet reported First Affiliated Hospital of Fujian Medical University 60 participants Est. completion 2025-08-01 1 site
    Other conditions: Insulinoma
    View official trial listing →
  • Status unknown NCT NCT05034783

    [68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients

    Not yet reported Peking Union Medical College Hospital 20 participants Est. completion 2023-06-01 1 site
    Other conditions: Insulinoma
    View official trial listing →
  • Completed NCT NCT05073692

    Comparison of Type 2 Diabetes Pharmacotherapy Regimens

    Kaiser Permanente 241981 participants Est. completion 2025-03-12 6 sites
    Type 2 diabetesCardiovascular disease
    View official trial listing →
  • Completed NCT NCT05136287

    SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.

    Jose Seijas Amigo 140 participants Est. completion 2024-01-01 11 sites
    Type 2 diabetes Other conditions: Weight Loss, Quality of Life, Safety Issues
    View official trial listing →
  • Status unknown NCT NCT05161429

    BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes

    Brigham and Women's Hospital 550000 participants Est. completion 2024-06-30 5 sites
    Type 2 diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT05220917

    Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

    Brigham and Women's Hospital 781430 participants Est. completion 2027-09-30 1 site
    Type 2 diabetes Other conditions: Cardiovascular Events, Renal Disease
    View official trial listing →
  • Status unknown NCT NCT05328843

    Study to Evaluate the Pharmacokinetic Characteristics of Pegylated Exenatide Injection (PB-119) in Subjects With Different Degrees of Renal Insufficiency and Matched Subjects With Normal Renal Function

    Not yet reported PegBio Co., Ltd. 24 participants Est. completion 2022-10-01 1 site
    Other conditions: Type2Diabetes
    View official trial listing →
  • Terminated NCT NCT05347147

    A Trial to Determine the Efficacy and Safety of Presendin in IIH

    Not yet reported Invex Therapeutics Ltd. 14 participants Est. completion 2023-10-20 24 sites
    Other conditions: Idiopathic Intracranial Hypertension
    View official trial listing →
  • Status unknown NCT NCT05418907

    Exendin PET/CT for Imaging of Paragangliomas

    Radboud University Medical Center 10 participants Est. completion 2024-12-01 1 site
    Other conditions: Paraganglioma
    View official trial listing →
  • Completed NCT NCT05610800

    Exenatide for Smoking Cessation and Prevention of Weight Gain

    Not yet reported The University of Texas Health Science Center, Houston 140 participants Est. completion 2026-03-10 2 sites
    Other conditions: Smoking Cessation, Weight Gain
    View official trial listing →
  • Status unknown NCT NCT05622123

    BetaFIT Study: Beta Cell Imaging After Faecal mIcrobiota Transplantation

    Not yet reported Radboud University Medical Center 20 participants Est. completion 2024-03-30 1 site
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT05670379

    Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant

    Not yet reported Vivani Medical, Inc 24 participants Est. completion 2025-08-21 1 site
    Other conditions: Overweight and Obesity, Type2diabetes
    View official trial listing →
  • Terminated NCT NCT05762744

    Pharmacogenomics of GLP1 Receptor Agonists

    Not yet reported University of Maryland, Baltimore 63 participants Est. completion 2022-10-31 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT06247748

    Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects

    Not yet reported Beijing Dongfang Biotech Co., Ltd. 28 participants Est. completion 2024-04-15 1 site
    Type 2 diabetes Other conditions: Overweight
    View official trial listing →
  • Withdrawn NCT NCT06252623

    Exenatide For Reducing the Reinforcing Effects of Cocaine

    Not yet reported Christopher D. Verrico Est. completion 2026-12-31 1 site
    Other conditions: Cocaine Use Disorder
    View official trial listing →
  • Active, not recruiting NCT NCT06254014

    A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients

    Not yet reported Beijing Dongfang Biotech Co., Ltd. 270 participants Est. completion 2026-06-30 1 site
    Type 2 diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT06257966

    A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin

    Not yet reported Beijing Dongfang Biotech Co., Ltd. 600 participants Est. completion 2026-11-30 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT06449235

    Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh

    Not yet reported Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders 938 participants Est. completion 2025-06 1 site
    Other conditions: Type2diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT07188545

    Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)

    Ohio State University 23280000 participants Est. completion 2029-06-30 1 site
    Metabolic syndrome
    View official trial listing →
  • Completed NCT NCT07340437

    Clinical Study of 18F-Exendin-4 in Insulinoma

    Sichuan Provincial People's Hospital 20 participants Est. completion 2025-12-31 1 site
    Other conditions: Insulinoma
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.